LEADER 03414nam  2200661Ia 450 
001 9910452566103321
005 20200520144314.0
010   $a0-19-174006-3
010   $a0-19-960718-4
010   $a1-283-58126-4
010   $a9786613893710
010   $a0-19-157545-3
035   $a(CKB)2550000000105507
035   $a(EBL)975600
035   $a(OCoLC)801363650
035   $a(SSID)ssj0000627964
035   $a(PQKBManifestationID)12276471
035   $a(PQKBTitleCode)TC0000627964
035   $a(PQKBWorkID)10701500
035   $a(PQKB)10109319
035   $a(MiAaPQ)EBC975600
035   $a(StDuBDS)EDZ0000091507
035   $a(Au-PeEL)EBL975600
035   $a(CaPaEBR)ebr10581627
035   $a(CaONFJC)MIL389371
035   $a(EXLCZ)992550000000105507
100   $a20090415d2008      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aVaccines for the prevention of cervical cancer$b[electronic resource] /$fedited by Peter L. Stern and Henry C. Kitchener
210   $aOxford $cOxford University Press$d2008
215   $a1 online resource (170 p.)
225 1 $aOxford oncology library
300   $aDescription based upon print version of record.
311   $a0-19-954345-3 
320   $aIncludes bibliographical references and index.
327   $aContents; Preface; Contributors; Abbreviations; Glossary; Part 1-Prevention and current treatment; 1 The UK cervical screening programme; 2 Management of cervical intraepithelial neoplasia (CIN); Part 2-HPV and disease; 3 Role of HPV in cervical carcinogenesis; 4 HPV and genital cancer: the essential epidemiology; 5 The role of HPV testing in cervical screening; Part 3-Immune control of HPV infection in cervical neoplasia; 6 Natural immune control of HPV infection; 7 Prophylactic HPV vaccines: pre-clinical and proof of principle studies; 8 Prophylactic HPV vaccination: current status
327   $a9 Introduction of HPV prophylactic vaccination Part 4-Challenges and future developments; 10 HPV vaccination in the developing world; 11 Screening post vaccination; 12 Second-generation HPV prophylactic vaccines; 13 Therapeutic HPV vaccines; 14 Conclusion; Index;
330   $aCervical cancer is the second most common form of cancer found in women and it is responsible for more than a quarter of a million deaths worldwide each year. With approximately 70% of cervical cancers now known to be caused by two types of the human papilloma virus (HPV), there is great interest surrounding the approval of the first preventative vaccines for clinical use. Despite this excitement, many questions remain about how the new vaccines should best be implemented and how cervical cancer screening will change following vaccination.Part of the Oxford Oncology Library series, this practice
410  0$aOxford oncology library.
606   $aCervix uteri$xCancer$xPrevention
606   $aCancer vaccines
608   $aElectronic books.
615  0$aCervix uteri$xCancer$xPrevention.
615  0$aCancer vaccines.
676   $a616.99/466
701   $aStern$b Peter L$0885338
701   $aKitchener$b Henry C$0885339
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910452566103321
996   $aVaccines for the prevention of cervical cancer$91976770
997   $aUNINA